APA (7th ed.) Citation

JE, P., DG, R., & LL, Y. C. (2023). Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors. Frontiers in endocrinology, 14, 951099. https://doi.org/10.3389/fendo.2023.951099

Chicago Style (17th ed.) Citation

JE, Pruett, Romero DG, and Yanes Cardozo LL. "Obesity-associated Cardiometabolic Complications in Polycystic Ovary Syndrome: The Potential Role of Sodium-glucose Cotransporter-2 Inhibitors." Frontiers in Endocrinology 14 (2023): 951099. https://doi.org/10.3389/fendo.2023.951099.

MLA (9th ed.) Citation

JE, Pruett, et al. "Obesity-associated Cardiometabolic Complications in Polycystic Ovary Syndrome: The Potential Role of Sodium-glucose Cotransporter-2 Inhibitors." Frontiers in Endocrinology, vol. 14, 2023, p. 951099, https://doi.org/10.3389/fendo.2023.951099.